MARBOWAP® Tablets

Marbofloxacin Tablets

For Veterinary Use Only

COMPOSITION

MARBOWAP® 20

Each tablet contains:

Marbofloxacin ........................................ 20 mg

Excipients ............................................. q.s.

MARBOWAP® 80

Each tablet contains:

Marbofloxacin ........................................ 80 mg

Excipients ............................................. q.s.

MARBOWAP® 160

Each tablet contains:

Marbofloxacin ...................................... 160 mg

Excipients ............................................. q.s.

PHARMACEUTICAL FORM

Scored oral tablets.

TARGET SPECIES

• Dogs

• Cats

INDICATIONS

MARBOWAP® Tablets are indicated for the treatment of bacterial infections caused by microorganisms susceptible to marbofloxacin.

Recommended for the treatment of:

• Skin and soft tissue infections (pyoderma, wounds, abscesses)

• Urinary tract infections

• Respiratory tract infections

• Periodontal and dental infections

• Otitis externa caused by susceptible bacteria

• Gastrointestinal bacterial infections

• Secondary bacterial infections associated with chronic dermatological conditions

Treatment should be based on bacterial culture and antimicrobial susceptibility testing whenever possible.

SPECTRUM OF ACTIVITY

Active against susceptible strains of:

• Escherichia coli

• Pasteurella multocida

• Proteus mirabilis

• Klebsiella spp.

• Enterobacter spp.

• Staphylococcus pseudintermedius

• Staphylococcus aureus

• Streptococcus spp.

• Bordetella bronchiseptica

• Pseudomonas aeruginosa (susceptible isolates)

PHARMACOLOGICAL PROPERTIES

Marbofloxacin is a third-generation fluoroquinolone antibiotic with bactericidal activity.

It inhibits bacterial DNA gyrase and topoisomerase IV, resulting in rapid bacterial cell death. Marbofloxacin has excellent oral bioavailability and penetrates effectively into skin, respiratory tissues, urinary tract, and soft tissues.

DOSAGE AND ADMINISTRATION

Administer orally.

Recommended dose:

2 mg/kg body weight once daily

Treatment duration:

• Skin infections: 5–14 days

• Urinary tract infections: 10–14 days

• Respiratory infections: 7–10 days

• Chronic pyoderma: up to 21 days, according to the veterinarian's assessment.

Always complete the prescribed course of treatment.

CONTRAINDICATIONS

• Do not use in animals with known hypersensitivity to fluoroquinolones.

• Do not administer to growing dogs of breeds known to be susceptible to cartilage disorders unless the benefit outweighs the risk.

• Not recommended for puppies during rapid growth phases except under veterinary supervision.

SPECIAL WARNINGS

Use antimicrobial agents responsibly to minimize the development of antimicrobial resistance.

Treatment should be guided by culture and susceptibility testing whenever possible.

ADVERSE REACTIONS

Occasionally:

• Vomiting

• Diarrhea

• Soft feces

• Reduced appetite

• Transient lethargy

Rarely:

• Neurological signs in predisposed animals

• Hypersensitivity reactions

USE DURING PREGNANCY AND LACTATION

Use only according to the benefit-risk assessment of the attending veterinarian.

DRUG INTERACTIONS

Avoid concurrent administration with:

• Antacids containing magnesium or aluminum

• Iron supplements

• Calcium supplements

• Sucralfate

These products may reduce marbofloxacin absorption.

OVERDOSE

Overdose may result in gastrointestinal disturbances or neurological signs.

Treatment is symptomatic and supportive.

STORAGE

Store below 25°C.

Protect from moisture and direct sunlight.

Keep in the original package.

SHELF LIFE

36 months.

PRESENTATION

Available strengths:

• MARBOWAP® 20

• MARBOWAP® 80

• MARBOWAP® 160

Pack sizes:

• 10 tablets

• 100 tablets